Yoseph Bornstein Sells 45,610 Shares of Microbot Medical Inc. (MBOT) Stock
Microbot Medical Inc. (NASDAQ:MBOT) Director Yoseph Bornstein sold 45,610 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $1.01, for a total transaction of $46,066.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Microbot Medical Inc. (NASDAQ MBOT) traded down 3.77% during midday trading on Thursday, reaching $1.02. 542,967 shares of the company traded hands. Microbot Medical Inc. has a one year low of $1.00 and a one year high of $15.66. The stock’s 50 day moving average is $1.14 and its 200 day moving average is $3.35. The company’s market capitalization is $44.92 million.
Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.44. On average, equities analysts anticipate that Microbot Medical Inc. will post ($25.02) earnings per share for the current year.
Separately, ValuEngine upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd.
An institutional investor recently raised its position in Microbot Medical stock. Bank of Montreal Can raised its position in shares of Microbot Medical Inc. (NASDAQ:MBOT) by 90,909.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,022 shares of the biotechnology company’s stock after buying an additional 20,000 shares during the quarter. Bank of Montreal Can owned about 0.07% of Microbot Medical worth $116,000 at the end of the most recent quarter. 4.72% of the stock is currently owned by hedge funds and other institutional investors.
Microbot Medical Company Profile
Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.
Receive News & Ratings for Microbot Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.